


## Candoxatril

<b>Cat. No.:</b>	HY-19649
<b>CAS No.:</b>	123122-55-4
<b>Molecular Formula:</b>	C <sub>29</sub> H <sub>41</sub> NO <sub>7</sub>
<b>Molecular Weight:</b>	515.64
<b>Target:</b>	Neprilysin
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Candoxatril is a neutral endopeptidase (NEP) inhibitor.
<b>IC<sub>50</sub> &amp; Target</b>	NEP <sup>[1]</sup> .
<b>In Vivo</b>	<p>While the NEP inhibitors have no significant effect on body weight, food and water intake, mean blood pressure or creatinine levels, they do increase cGMP levels in the urine and affected hematopoiesis in an anti-inflammatory way. Moreover, a-SMA deposition in the kidney cortex is inversely correlated with cGMP elevation suggesting a NEP dependent antifibrotic effect. High quality mRNA profiles are obtained with at least 8 independent samples per treatment group. The data confirms the cGMP dependent anti-fibrotic action of Sol-1 and further supports the potential therapeutic actions of this neutral endopeptidase inhibitor<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

### PROTOCOL

<b>Animal Administration</b> <sup>[2]</sup>	<p>Mice<sup>[2]</sup></p> <p>Mice (n=10 per group) subjected to UUO are treated for 1 week with either Solvent, SOL-1 (NEP-/ECE-inhibitor two doses), Candoxatril (reference NEP inhibitor) or losartan (angiotensin AT1-receptor antagonist) and compared to sham operated animals<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
---	---

### REFERENCES

[1]. Bevan EG, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. *J Hypertens.* 1992 Jul;10(7):607-13.

[2]. M Aleksinskaya, et al. Neutral endopeptidase inhibitors SOL-1 and candoxatril counteract kidney fibrosis by reducing myofibroblast formation in mouse UUO model. *Bmc Pharmacology & Toxicology*, 2013, 14 (1) :1-2.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA